Semaglutide and cancer: A systematic review and meta-analysis
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402123001303?via=ihub
French national health care insurance system database has suggested 1-3 years use of glucagon like peptide-1 receptor agonists (GLP1RA) (exenatide, li...
Conclusion: Semaglutide use in RCTs and real-world studies was not associated with an increased risk of any types of cancer, and this conclusion is supported by a high grade of evidence.
Share
Incretin Analogs for Weight Management in Adults Without Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37522468/
All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.
Conclusions: All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.
Share
Conclusions/Relevance: Discontinuation of Ozempic should be considered prior to general anesthesia due to gastrointestinal side effects including delayed gastric emptying. As the popularity of Ozempic grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative consideration.
Share
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
Source : https://www.sciencedirect.com/science/article/abs/pii/S0196978123001365?via=ihub
Novel dual agonists for the glucagon-like peptide-1 (GLP-1) and Y2 receptor hold the potential for enhanced efficacy over GLP-1 receptor (GLP-1R) agon...
Conclusions/Relevance: These results indicate the potential of developing xGLP/PYY-6 as an antiobesity, lipid regulation, antisteatotic, and antidiabetic agent.
Share
Pediatric Obesity: Complications and Current Day Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37511966/
Obesity affects approximately 1 in 5 youth globally and increases the risk of complications during adolescence and young adulthood, including type 2 diabetes, dyslipidemia, hypertension, non-alcoholic fatty liver disease, obstructive...
Conclusions/Relevance: Once identified, pediatric obesity should always be managed with lifestyle modification. However, adolescents with obesity may also benefit from anti-obesity medications (AOM), several of which have been approved for use in adolescents by the US Food and Drug Administration, including liraglutide,...
Share